
Roche
OrganizationHeard in 31 episodes across 17 shows since Jan 2026
Roche is a Swiss multinational healthcare company operating through Pharmaceuticals and Diagnostics divisions. It develops and commercializes medicines—particularly in oncology, immunology, neuroscience and other specialty areas—and diagnostic tests and technologies; the podcast references primarily concern its pharmaceutical pipeline, licensing and acquisitions, including China partnerships and metabolic-disease programs.
Episodes
This week
Expert statements
Share of the conversation
Mentions of Roche per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Aug 28 | 0.01‰ | 1 |
| Sep 14 | 0.01‰ | 1 |
| Sep 22 | 0.03‰ | 3 |
| Sep 23 | 0.04‰ | 1 |
| Oct 4 | 0.01‰ | 1 |
| Oct 19 | 0.01‰ | 1 |
| Oct 20 | 0.04‰ | 4 |
| Oct 26 | 0.04‰ | 1 |
| Oct 27 | 0.02‰ | 1 |
| Oct 28 | 0.03‰ | 2 |
| Oct 30 | 0.05‰ | 2 |
| Nov 9 | 0.01‰ | 1 |
| Nov 11 | 0.02‰ | 1 |
| Nov 14 | 0.02‰ | 1 |
| Nov 17 | 0.05‰ | 4 |
Email alert
Email me when Roche comes up on a podcast
One email a week at most, with the new episodes that mention Roche. Free, no account needed, unsubscribe in one click.
What experts have said about Roche
2 statements · 2 positive
Roche's Devaracib reduced death risk 44% and progression risk 42% versus older KRAS inhibitors.
“Devaracib outperformed them. It cut the risk of death by 44% and cut the risk of progression by 42%.”
Open the episode · 419: Assessing Merck and Moderna's mRNA cancer vaccineListen at 10:55
Devaracib will become standard of care in second-line treatment.
“this will become standard of care in this second line setting.”
Open the episode · 419: Assessing Merck and Moderna's mRNA cancer vaccineListen at 11:11
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
31 episodes featuring Roche, newest first
- Nov 20, 2026
Biotech weighs AI disruption against a stronger 2027 deal cycleBiotech HangoutNov 20, 2026 - Nov 17, 2026
Chip controls test Trump’s Asia strategyWSJ What’s NewsNov 17, 2026 - Nov 17, 2026
Kim Kardashian weighs acting ambitions against life in publicNot Skinny But Not FatNov 17, 2026 - Nov 17, 2026
Biotech bets meet a pivotal FDA succession fightBioCentury This WeekNov 17, 2026 - Nov 14, 2026
OTC Markets makes the case for rebuilding public-company financeMonetary Matters with Jack FarleyNov 14, 2026 - Nov 13, 2026
Biotech launches expose the gap between forecasts and adoptionBiotech HangoutNov 13, 2026